Grace Therapeutics (GRCE) Gross Margin (2020 - 2021)
Grace Therapeutics (GRCE) posted Gross Margin of 65.22% for Q1 2021, up 17.39% sequentially from 55.56% in Q4 2020.
Grace Therapeutics (GRCE) Gross Margin (2020 - 2021) Analysis & Trends
Grace Therapeutics has reported Gross Margin for 2 years, with the latest figure at 65.22% in Q1 2021.
- Quarterly Gross Margin changed N/A year-over-year to 65.22% in Q1 2021, while the trailing twelve-month figure through Mar 2022 was 61.22% (changed N/A YoY) and the FY2021 annual result came in at 61.22%, changed N/A from the prior year.
- Gross Margin advanced to 65.22% in Q1 2021 per GRCE's latest filing, from 55.56% in the prior quarter.
- Over five years, Gross Margin peaked at 65.22% in Q1 2021 and troughed at 55.56% in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Grace Therapeutics | 37.99 Mn | 37.99 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 65.22% |
| Dec 31, 2020 | 55.56% |